Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

Burton L. Eisenberg, Jonathan Harris, Charles D. Blanke, George D. Demetri, Michael C. Heinrich, James C. Watson, John P. Hoffman, Scott Okuno, John M. Kane, Margaret Von Mehren

Research output: Contribution to journalArticlepeer-review

292 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665'. Together they form a unique fingerprint.

Medicine & Life Sciences